I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

In Japan, the levonorgestrel intrauterine system (LNG-IUS) was included in the public insurance plan for the treatment of hypermenorrhea and dysmenorrhea in 2014.\[[@ref1]\] Migration of an intrauterine device (IUD) into the peritoneal cavity is rare, with an incidence rate of 0%--0.28%.\[[@ref2]\] In this report, we describe a case in which the LNG-IUS was misplaced outside of the uterine cavity, which required removal from the retroperitoneal cavity using a laparoscopic approach.

C[LINICAL]{.smallcaps} I[MAGE]{.smallcaps} {#sec1-2}
==========================================

A 29-year-old female, gravida 3, para 1, had previously undergone cervical conization, for the treatment of carcinoma *in situ* of the uterine cervix, at the age of 22 years. An LNG-IUS was inserted into the uterus for the treatment of dysmenorrhea and to prevent cervical stenosis at the local clinic at the age of 24 years.

The patient visited our hospital after surgery with persisting abdominal pain and was admitted for investigation. On speculum examination, the LNG-IUS thread was visible; however, due to the previous conization procedure, the location of the uterine cervical canal was difficult to confirm. The foreign body could not be located during vaginal examination. For evacuation of the hematoma, we proceeded the dilation using a 14-Fr catheter, and we attempted to locate and remove the misplaced LNG-IUS \[[Figure 1](#F1){ref-type="fig"}\]. As we were unable to locate the LNG-IUS, intraoperative radiography was performed, with the device visible outside of the uterine cavity \[[Figure 2](#F2){ref-type="fig"}\].

![Intraoperative abdominal radiograph at dilation and curettage point showing the location of the levonorgestrel intrauterine system outside of the uterine cavity](GMIT-8-86-g001){#F1}

![Postoperative at dilation and curettage point computed tomography confirming the location of the levonorgestrel intrauterine system in the retroperitoneal space. The catheter was implanted during initial dilation and curettage to prevent restenosis](GMIT-8-86-g002){#F2}

Two months after the transcervical procedure, we performed a laparoscopic procedure to remove the foreign body. We inserted a 12-mm trocar through the umbilicus and two 5-mm trocars at both lateral regions and the lower abdomen. After confirmation of the position of the device in the left side retroperitoneal space near ureter \[[Figure 3](#F3){ref-type="fig"}\], we confirmed the absence of perforation or adhesions to adjacent organs by laparoscopic observation.

![Localization of the levonorgestrel intrauterine system under the left ovary in the pelvic peritoneum](GMIT-8-86-g003){#F3}

The ureters were noted to have bilateral peristalsis transperitoneally. A 1.5-cm linear incision was made in the long axis of the device using monopolar electrical scalpel. The device was coherent at the retroperitoneal space, and it was removed carefully. The chromotubation was successfully performed to confirm the tubal patency. The retroperitoneal wound was carefully cover the with adhesion barrier (Seprafilm, Kaken Pharmaceutical Co., Ltd. Tokyo, Japan).

The operation time was 1 h 21 min, with minimal blood loss. Abdominal pain resolved completely after surgery.

D[ISCUSSION]{.smallcaps} {#sec1-3}
========================

In our case, the LNG-IUS was incorrectly placed in the retroperitoneum at the time of initial insertion. A previous review of women with a misplaced LNG-IUS indicated that 50% were asymptomatic, 28.7% became pregnant, 17.8% reported abdominal pain, and 4.7% presented with irregular vaginal bleeding.\[[@ref3]\] The patient in our case was admitted due to persisting lower abdominal pain and vaginal bleeding, both of which were initially considered as resulting from an intrauterine hematoma.

Certainly, there is no need for the removal of an intra-abdominal LNG-IUS in asymptomatic cases,\[[@ref4]\] except for the purpose of planning a pregnancy, which would require removal to lower the plasma levels of LNG to permit ovulation.\[[@ref5]\]

In our case, we suspected that the LNG-IUS was incorrectly placed into the retroperitoneum, through the posterior vaginal vault, and did not migrate from the uterus into the peritoneal cavity due to uterine perforation.\[[@ref6]\] Certainly, IUD migration can cause serious complications, including bowel and bladder perforation, ileus, abdominal abscess, and fistula formation.\[[@ref7]\] Kno *et al*. reported that an abnormal uterine orientation, such as retroversion or acute reflection, increases the risk of perforation, with 42% of uterine perforation occurring in patients with a retroverted uterus, with the incidence rate of uterine retroversion estimated at 20%--25%.\[[@ref8]\] Although 43% of women in Kno\'s case series (16 of 37 cases) did not experience symptoms associated with a perforation of the uterus, the authors did still advocate for the prompt localization and removal of the IUD in these cases to prevent complications and limit the need for a more extensive procedure later. Based on our experience, we propose that it is important to be cognizant of the possibility of IUD migration and therefore to obtain at a minimum upper and lower abdominal radiographs. It would also be advisable to clearly explain the possible complications to patients and stress the importance of annual examinations and regular removal of the IUD.

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

We describe a case of IUD misplacement in the retroperitoneal space that required removal using a laparoscopic technique. Misplacement of an IUD outside of the uterus after a conization procedure should be suspected in women with persisting symptoms, and this possibility diligently assessed.
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